NCT03807687Recruiting
Registry of Pancreatic Disease
Registry of Subjects Affected by Pancreatic Disease and Evaluated at the Pancreas Institute of Verona
Source: ClinicalTrials.gov · Last updated 17 Jan 2019 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This clinical data registry records information about the health status and healthcare performances received by participants affected by every type of pancreatic disease or disorder. All data (demographic, clinical, biochemical, radiological, pharmacological, genetic...) and audio and/or video recording from operative room are collected in order to be used for prospective or retrospective studies.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3000 (estimated)
- First submitted
- 15 Jan 2019
- Start date
- 1 Dec 2016
- Primary completion date
- 1 Dec 2046
- Lead sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
- Diseases
- Pancreatic cancer
- NCT number
- NCT03807687
What you commit to
- Study type: Observational
- Planned participants: 3000
- From 1 Dec 2016 to the primary completion date, 1 Dec 2046
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- physically or mentally inability to provide consent
Who the study is looking for
- any type of pancreatic disease: inflammatory and neoplastic (including solid and cystic lesions)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| AOUI Verona Coordinator of this site? Confirm its status | Verona | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.